Thyroid disease and lipids

被引:478
作者
Duntas, LH [1 ]
机构
[1] Univ Athens, Sch Med, Evgenidion Hosp, Endocrine Unit, Athens 11528, Greece
关键词
D O I
10.1089/10507250252949405
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The composition and the transport of lipoproteins are seriously disturbed in thyroid diseases. Overt hypothyroidism is characterized by hypercholesterolaemia and a marked increase in low-density lipoproteins (LDL) and apolipoprotein B (apo A) because of a decreased fractional clearance of LDL by a reduced number of LDL receptors in the liver. The high-density lipoprotein (HDL) levels are normal or even elevated in severe hypothyroidism because of decreased activity of cholesteryl-ester transfer protein (CETP) and hepatic lipase (HL), which are enzymes regulated by thyroid hormones. The low activity of CETP, and more specifically of HL, results in reduced transport of cholesteryl esters from HDL2 to very low-density lipoproteins (VLDL) and intermediate low-density lipoprotein (IDL), and reduced transport of HDL2 to HDL3. Moreover, hypothyroidism increases the oxidation of plasma cholesterol mainly because of an altered pattern of binding and to the increased levels of cholesterol, which presents a substrate for the oxidative stress. Cardiac oxygen consumption is reduced in hypothyroidism. This reduction is associated with increased peripheral resistance and reduced contractility. Hypothyroidism is often accompanied by diastolic hypertension that, in conjunction with the dyslipidemia, may promote atherosclerosis. However, thyroxine therapy, in a thyrotropin (TSH)-suppressive dose, usually leads to a considerable improvement of the lipid profile. The changes in lipoproteins are correlated with changes in free thyroxine (FT4) levels. Hyperthyroidism exhibits an enhanced excretion of cholesterol and an increased turnover of LDL resulting in a decrease of total and LDL cholesterol, whereas HDL are decreased or not affected. The action of thyroid hormone on Lp(a) lipoprotein is still debated, because both decrease or no changes have been reported. The discrepancies are mostly because of genetic polymorphism of apo(a) and to the differences between the various study groups. Subclinical hypothyroidism (SH) is associated with lipid disorders that are characterized by normal or slightly elevated total cholesterol levels, increased LDL, and lower HDL. Moreover, SH has been associated with endothelium dysfunction, aortic atherosclerosis, and myocardial infarction. Lipid disorders exhibit great individual variability. Nevertheless, they might be a link, although it has not been proved, between SH and atherosclerosis.
引用
收藏
页码:287 / 293
页数:7
相关论文
共 78 条
  • [51] SERUM-LIPIDS AND APOLIPOPROTEIN-A-I, APOLIPOPROTEIN-A-II AND APOLIPOPROTEIN-B IN PRIMARY HYPOTHYROIDISM BEFORE AND DURING TREATMENT
    MULS, E
    ROSSENEU, M
    BLATON, V
    LESAFFRE, E
    LAMBERIGTS, G
    DEMOOR, P
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1984, 14 (01) : 12 - 15
  • [52] STIMULATION OF HEPATIC BETA-HYDROXY-BETA-METHYLGLUTARYL COENZYME-A REDUCTASE-ACTIVITY IN HYPOPHYSECTOMIZED RATS BY L-TRIIODOTHYRONINE
    NESS, GC
    DUGAN, RE
    LAKSHMANAN, MR
    NEPOKROEFF, CM
    PORTER, JW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1973, 70 (12) : 3839 - 3842
  • [53] NIKKILA EA, 1979, LANCET, V1, P391
  • [54] HYPERLIPIDEMIA IN PATIENTS WITH PRIMARY AND SECONDARY HYPOTHYROIDISM
    OBRIEN, T
    DINNEEN, SF
    OBRIEN, PC
    PALUMBO, PJ
    [J]. MAYO CLINIC PROCEEDINGS, 1993, 68 (09) : 860 - 866
  • [55] INCREASED MEAN SERUM THYROTROPIN IN APPARENTLY EUTHYROID HYPERCHOLESTEROLEMIC PATIENTS - DOES IT MEAN OCCULT HYPOTHYROIDISM
    PALLAS, D
    KOUTRAS, DA
    ADAMOPOULOS, P
    MARAFELIA, P
    SOUVATZOGLOU, A
    PIPERINGOS, G
    MOULOPOULOS, SD
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1991, 14 (09) : 743 - 746
  • [56] Sex steroids, lipids, and lipoprotein cholesterols in women with subclinical and overt hypothyroidism before and after L-thyroxine therapy
    Paoli, M
    Bellabarba, G
    Velazquez, E
    Mendoza, S
    Molina, C
    Wang, P
    Glueck, CJ
    [J]. CLINICA CHIMICA ACTA, 1998, 275 (01) : 81 - 91
  • [57] LONG-TERM THYROID REPLACEMENT THERAPY AND LEVELS OF LIPOPROTEIN(A) AND OTHER LIPOPROTEINS
    PAZOS, F
    ALVAREZ, JJ
    RUBIESPRAT, J
    VARELA, C
    LASUNCION, MA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (02) : 562 - 566
  • [58] RIDGWAY EC, 1981, J CLIN ENDOCR METAB, V53, P1238, DOI 10.1210/jcem-53-6-1238
  • [59] THE AGING THYROID - THYROID-DEFICIENCY IN THE FRAMINGHAM-STUDY
    SAWIN, CT
    CASTELLI, WP
    HERSHMAN, JM
    MCNAMARA, P
    BACHARACH, P
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1985, 145 (08) : 1386 - 1388
  • [60] SCOTTOLINI AG, 1980, CLIN CHEM, V26, P584